Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.0350 (-2.38%) ($9.0350 - $9.0350) on Thu. Apr. 7, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.3% (three month average) | RSI | 35 | Latest Price | $9.0350(-2.38%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.4% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(63%) IWO(50%) IWC(47%) IWM(47%) XBI(44%) | Factors Impacting FOLD price | FOLD will decline at least -2.15% in a week (0% probabilities). VIXM(-26%) VXX(-12%) UUP(-10%) UNG(-9%) EDOC(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.15% (StdDev 4.3%) | Hourly BBV | -0.8 () | Intraday Trend | 0% | | | |
|
Resistance Level | $9.44 | 5 Day Moving Average | $9.36(-3.47%) | 10 Day Moving Average | $9.44(-4.29%) | 20 Day Moving Average | $9.44(-4.29%) | To recent high | -20.8% | To recent low | 14.6% | Market Cap | $2.333b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |